Taken together, these results suggest that IL‐1R antagonism inhibits extramedullary myelopoiesis in RA, which is associated with a reduction in blood monocytes and an improvement in atherosclerotic lesion regression. Here, IL1R1 is linked to rheumatoid arthritis.